Bioclinica Acquires Saliency

Article

Bioclinica has announced that it has acquired Silicon Valley-based Saliency. Bioclinica will integrate the company's AI technology into its Imaging.

The Saliency platform uses proprietary algorithms to quickly build and train AI models from a small number of de-identified images. These newly created models can then be used to screen, redact, or interpret medical images to support a wide range of therapeutic areas.

Saliency's co-founders, Kevin Thomas, MD/PhD, candidate at Stanford University School of Medicine and Łukasz Kidziński, PhD, formerly of Stanford's Bioengineering & Statistics, will join Bioclinica's Image Science team.

For more information, click here.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Recent Videos
Related Content
© 2025 MJH Life Sciences

All rights reserved.